Original Source Material
Agency: Guidance Favors Market Innovation Over Federal Scrutiny New artificial intelligence-enabled health wearable devices and clinical decision support software will not face U.S. Food and Drug Administration regulatory scrutiny, providing the technology meets certain criteria, such as being "low-risk," the agency said this week.